Beste apotheek van Nederland

Bancroft J, Smith G, Munoz M et al. Erectile response to visual
erotic stimuli before and after intracavernosal papaverine, and
its relationship to nocturnal penile tumescence and psychometric
assessment. Br J Urol 1991;68(6):629-638.
Beretta G, Marzotto M, Zanollo A et al. Office treatment:
intracavernous injections of prostaglandin E1 (PG E1) and
improvement of spontaneous erections. Acta Eur Fertil
1991;22(4):221-223.
Bird T D, Lipe H P, Crabtree L D. Impotence associated with
the Charcot-Marie-Tooth syndrome. Eur Neurol
1994;34(3):155-157.
Brown S L, Haas C A, Koehler M et al. Hepatotoxicity related
to intracavernous pharmacotherapy with papaverine. Urology
1998;52(5):844-847.
Casella R, Deckart A, Bachmann A et al. The patient's selfevaluation
better predicts the degree of erectile dysfunction than
the response to intracavernous alprostadil testing. Urol Int
2004;72(3):216-220.
Chatterjee R, Kottaridis P D, McGarrigle H H et al.
Management of erectile dysfunction by combination therapy
with testosterone and sildenafil in recipients of high-dose
therapy for haematological malignancies. Bone Marrow
Transplant 2002;29(7):607-610.
Chun S S, Fenemore J, Heaton J P et al. Enhancement of erectile
responses to vasoactive drugs by a variable amplitude oscillation
device. Int J Impot Res 1996;8(4):221-225.
Dinsmore W W, Alderdice D K. Vasoactive intestinal
polypeptide and phentolamine mesylate administered by
autoinjector in the treatment of patients with erectile dysfunction
resistant to other intracavernosal agents. Br J Urol
1998;81(3):437-440.
Fein R L. Classification of sexual dysfunction for management
of intracavernous medication-induced erections.[see comment].
Br J Urol 1990;143(2):298-301.
Goonawardena S A, de Silva W A, Ketheeswaran T.
Pharmacologically induced penile erections in the assessment
and treatment of erectile impotence: a preliminary study of 100
patients. Ceylon Med J 1997;42(2):72-74.
Greco E, Balbi P P, Virag R. Self intra-cavernous injections as a
successful treatment in pure neurogenic impotence. Riv Neurol
1991;61(1):35-38.
Kadioglu A, Erdogru T, Tellaloglu S. Combined intracavernous
injection of papaverine and stimulation (CIS) test. J Androl
1994;15 Suppl50S-53S.
Katlowitz N M, Albano G J, Morales P et al. Potentiation of
drug-induced erection with audiovisual sexual stimulation.
Urology 1993;41(5):431-434.
Katlowitz N, Albano G J, Patsias G et al. Effect of
multidose intracorporeal injection and audiovisual
sexual stimulation in vasculogenic impotence.
Urology 1993;42(6):695-697.
Kim J M, Joh Y D, Huh J D et al. Doppler sonography
of the penile cavernosal artery: comparison of
intraurethral instillation and intracorporeal injection of
prostaglandin E1. J Clin Ultrasound 2001;29(5):273­
278.
Knispel H H. Penile venous surgery in impotence:
results in highly selected cases. Urol Int
1991;47(3):144-148.
Kromann-Andersen B. Intracavernosal
pharmacotherapy with injection pen. Lancet
1988;1(8575-6):54-59.
Mansi M K, Alkhudair W K, Huraib S. Treatment of
erectile dysfunction after kidney transplantation with
intracavernosal self-injection of prostaglandin E1. Br J
Urol 1998;159(6):1927-1930.
McMahon C G. A pilot study of the role of
intracavernous injection of vasoactive intestinal
peptide (VIP) and phentolamine mesylate in the
treatment of erectile dysfunction. Int J Impot Res
1996;8(4):233-236.
McMahon C G. Priapism associated with concurrent
use of phosphodiesterase inhibitor drugs and
intracavernous injection therapy. Int J Impot Res
2003;15(5):383-384.
Metawea B, El-Nashar A R, Gad-Allah A et al.
Intracavernous papaverine/phentolamine-induced
priapism can be accurately predicted with color
Doppler ultrasonography. Urology 2005;66(4):858­
860.
Mirone V, Imbimbo C, Fabrizio F et al. Ketanserin
plus prostaglandin E1 (PGE-1) as intracavernosal
therapy for patients with erectile dysfunction
unresponsive to PGE-1 alone. Br J Urol
1996;77(5):736-739.
Nagai A, Kusumi N, Tsuboi H et al. Intracavernous
injection of prostaglandin E1 is effective in patients
with erectile dysfunction not responding to
phosphodiseterase 5 inhibitors. Acta Med Okayama
2005;59(6):279-280.
Nalesnik J G, Jones L, Kraus S R. Group B
streptococcal septicemia following intracavernous
injection therapy for erectile dysfunction in diabetes.
Br J Urol 2004;172(1):151-152.
Pagani E, Puech-Leao P, Glina S et al. The value of a
second injection on the pharmaco-induced erection
test. Int J Impot Res 1997;9(3):167-168.
D-156